MPN Workshop of the Carolinas 2025 | The ECLIPSE-PV trial: comparing two dosing regimens of ropeginterferon alfa-2b in patients with PV

So the ECLIPSE study, it’s an important study. It’s really asking a fundamental question that’s important for the practice of medicine, which is, what is the best strategy for titrating up our dose of ropeginterferon in PV patients? So currently right now, it’s approved based off the PROUD-PV study where you start at 50 micrograms and then you dose up every two weeks. So it can take 14, 16 weeks to get to 500 micrograms, which is presumably the top dose and the gold standard dose of patients with PV. 

The ECLIPSE study is asking a more relevant, perhaps a clinically relevant question, that is often asked in clinical trials. It’s comparing an accelerated phase approach, so 250, 350, 500 of ropeginterferon alfa-2b versus the standard, you know, slower-paced approach. But the question is, you know, which one ultimately gets to the endpoint faster of count control? I think tolerability would be important. And then ultimately, do patients get not just, I would say, CHR faster, but what are the molecular responses if you get up faster? Does it matter? And I think that’s an unanswered question. There are some of those folks in this MPN community that think faster and harder hitting the clone might be better. And then some might think slow start and balancing toxicities. We could debate it all day long, but I think the trial is important because the trial will actually answer that.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.